Phastar Appoints Graham Clark as New Chief Executive Officer

Image of Graham Clark, new CEO of Phastar

Phastar Sets Course for Further Growth with New CEO Appointment

London, UK and Durham (NC), US – 10th August 2023. Phastar, a global specialist biometrics contract research organization (CRO), today announced the appointment of Graham Clark as the new Chief Executive Officer. Amid ambitious growth plans and organizational changes, Clark will succeed Andrew MacGarvey as CEO and further boost the paradigm shift in delivery of world-class data quality oversight. Having positioned the company for success, MacGarvey will assume the Chief Operating Officer (COO) role, maintaining his Board position.

As former Managing Director with Phlexglobal, a global authority in Trial Master File (TMF) technology and services, Clark adds strong operational and commercial experience to the Phastar team. An accomplished leader with a proven track record in Operations, Strategy and Change management, he brings over 25 years’ experience in life sciences, financial, and professional services organizations.

Continue Reading

Phastar's B Corp™ certification affirms its status as a 'force for good' organisation

Image of B Corp certification

International certification recognizes leading global specialist biometrics CRO’s commitment and leadership in corporate social responsibility and sustainable business practices.

London, UK and Durham, NC – 11th July 2023.  Phastar, a global specialist biometrics contract research organization (CRO), have become a certified B Corporation®. It comes after a stringent 12-month review to ensure protocols and procedures reflect the company’s commitment to high environment, social, and governance (EGS) standards.

Certified B Corporations® (B Corps™) are for-profit companies that meet the highest standards of verified social and environmental performance, transparency, and legal accountability.  

As part of a rigorous process, the assessment body B Lab Global reviewed Phastar’s impact across the five key areas: governance, workers, environment, community, and customers. The minimum threshold for certification was 80 points, but Phastar achieved an impressive 91.4.

Continue Reading

Phastar Statistics Manager Wins Prestigious DIA Award

Stephen Corson, Statistics Manager at specialist biometrics contract research organization (CRO) Phastar, has been chosen to receive the DIA 2023 Global Inspire Award for Community Engagement.

This prestigious award recognises the outstanding contribution of DIA Community Chairs who consistently drive engagement and promote knowledge sharing, while advancing thought leadership within the membership community.

Stephen commented: “The DIA Community is such a constructive, collaborative space with everyone inspired by their work which can really benefit people. It already feels a privilege to be able to share what knowledge I can to the table, so it is a fantastic bonus to be recognised by the DIA community. Education around data science is crucial to making clinical trial processes more efficient and I get such a buzz from working alongside like-minded, incredible people, both at Phastar and DIA, who are committed to knowledge sharing and collaboration.”

Continue Reading

Phastar Supports Great Ormond Street Rare Disease Study Through Pro Bono Scheme

London, UK and Durham, NC – April 13, 2023 – Phastar has supported a Great Ormond Street Hospital-sponsored study into new treatments for children with severe combined immunodeficiency (SCID). The company provided pro bono support from its specialist statisticians, data managers and programmers for the study, testing efficacy and safety of cryopreserved haematopoietic stem cells for transplant.

SCID is the name given to a group of rare, inherited disorders that cause major abnormalities of the immune system. Germs that would be relatively harmless to healthy individuals can cause serious and life-threatening illness in a child with SCID. Adenosine deaminase (ADA)-SCID was identified almost four decades ago and represents approximately 15-20% of all cases of SCID. The majority of ADA-SCID patients are diagnosed in the first year of life. The patients rarely survive beyond 1 to 2 years unless immune function is restored or contact with pathogens is avoided by creating a sterile environment around the patient (the so-called “bubble-children”). In most cases, haematopoietic stem cell transplantation offers the only long-term cure.

Gene therapy offers an alternative treatment for ADA-SCID whereby a correctly functioning copy of the ADA gene is introduced into haematopoietic stem cells (HSCs) that have been harvested from the patients themselves using a gene transfer vector. These transduced cells are then returned to the patient where they initiate immune reconstitution much like HSCs from a healthy donor.

Continue Reading

Phastar enhances Data Visualization and Analytics solution through acquisition of S-Cubed ApS

London, UK and Durham, NC – January 10, 2023 – Phastar announced today the acquisition of S-Cubed ApS, a specialist biometrics and data visualisation company. The deal takes the Phastar group to around 550 people worldwide and strengthens the company's position in the Nordic region. 

Andrew MacGarvey, CEO of Phastar, commented, "I am pleased we have been able to bring S-Cubed into the Phastar family. In doing so, we can solidify our presence in the Nordic region and add significant capability in data visualisation. The S-Cubed team share the Phastar values and bringing the two businesses together benefits both the organisations and their respective customers. Phastar continues to grow, and I am excited to start the New Year with an enhanced offering for our customers." 

Scott McGregor, Managing Director S-Cubed, said, "We are delighted to bring S-Cubed into the Phastar group. As we learned more about Phastar and the management team, it became apparent that our philosophies were closely aligned. In addition, being part of a global entity will allow us to deliver increased services in the Nordics. We look forward to making our successful data visualisation product available to a wider customer base."

Continue Reading